Hodgkin’s disease is highly curable today. For early stages (stages I, II, and IIIA), radiotherapy is the treatment of choice. Although this treatment has been successful for more than three decades, no definite recommendations can be made as yet regarding the dose requirements because considerable controversy still exists on this subject. Here we review the literature in terms of dose-response data for Hodgkin’s disease. This review is intended to serve as a guide for a practicing clinician who is deciding on dose selection for the radiotherapy of Hodgkin’s disease. There is a trend toward higher in-field disease control at lower doses of megavoltage radiotherapy. There is also a suggestion that, currently, more than the necessary doses are being used for in-field disease control. Results should be reported in terms of disease burden so that dose prescriptions can be tailored to the malignant-cell burden in the future.

Keywords:
Hodgkin’s disease, Dose response, Curative dose, Disease burden
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.